Lindis Blood Care to Unveil REMOVE Study Results on CATUVAB® at NATA24 Symposium

Lindis Blood Care GmbH has announced its participation in the NATA24 Annual Symposium in Bologna, Italy, from April 18-20, 2024, where it will present the outcomes of the REMOVE clinical certification study for its innovative medical device, CATUVAB®. Designed for the safe management of intraoperative blood during cancer surgeries, CATUVAB® aims to reduce the risks associated with donor blood transfusions by allowing patients to receive their own, purified blood.

Prof. Dr. med. Patrick Meybohm will share the first safety and efficacy findings from the REMOVE study, which evaluates the device’s ability to aggregate and remove tumor cells and lymphocytes from intraoperative blood. With the positive results, Lindis Blood Care seeks EU and US approval for CATUVAB®, aspiring to offer it as the first approved device of its kind for cancer patients, potentially avoiding complications like immunosuppression and increased tumor recurrence associated with donor blood.

The REMOVE study, a significant clinical trial involving more than 130 patients, tested CATUVAB®'s efficacy in excising EpCAM-positive tumor cells from the blood during surgeries, offering a safer alternative for autologous blood transfusion. The symposium appearance marks a crucial step in Lindis Blood Care's mission to integrate CATUVAB® into standard patient blood management protocols, emphasizing its potential in improving surgical outcomes and patient safety.